文献リスト

1）Raghu G, Collard HR, Egan JJ, et al; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183: 788-824

2）日本呼吸器学会，びまん性肺疾患診断・治療ガイドライン作成委員会．特発性間質性肺炎―診断と治療の手引き 第2版．東京：南江堂；2011

3）Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011; 183（4）: 431-40

4）Nishiyama O, Taniguchi H, Kondoh Y, et al; A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis. Eur Respir J. 2010; 36: 1067-72

5）Lynch DA, Godwin JD, Safrin S, et al; Idiopathic Pulmonary Fibrosis Study Group. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med. 2005; 172: 488-93

6）Sumikawa H, Johkoh T, Colby TV, et al. Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival. Am J Respir Crit Care Med. 2008; 177: 433-9

7）Flaherty KR, Thwaite EL, Kazerooni EA, et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax. 2003; 58（2）: 143-8

8）Hamada K, Nagai S, Tanaka S, et al. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest. 2007; 131: 650–6

9）Cottin V, Nunes H, Brillet PY, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J. 2005; 26: 586-93

10）Okamoto M, Hoshino T, Kitasato Y, et al. Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias. Eur Respir J. 2011; 37（5）: 1119-27

11）Richards TJ, Kaminski N, Baribaud F, et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012; 185（1）: 67-76

12）Kondoh Y, Taniguchi H, Kawabata Y, et al. Acute exacerbation in idiopathic pulmonary fibrosis-analysis of clinical and pathologic findings in three cases. Chest. 1993; 103: 1808-12

13）谷口博之，近藤康博．特発性肺線維症の急性増悪の新しい診断基準について．厚生労働科学研究費補助金難治性疾患克服研究事業びまん性肺疾患調査研究班．平成15年度研究報告書．2004, p.114-9

14）Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007; 176: 636-43

15）Song JW, Hong SB, Lim CM, et al. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J. 2011; 37（2）: 356-63

16）Kondoh Y, Taniguchi H, Katsuta T, et al. Risk factors of acute exacerbation of idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2010; 27（2）: 103-10

17）Judge EP, Fabre A, Adamali HI, et al. Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Eur Respir J. 2012; 40（1）: 93-100

18）Monaghan H, Wells AU, Colby TV, et al. Prognostic implications of histologic patterns in multiple surgical lung biopsies from patients with idiopathic interstitial pneumonias. Chest. 2004; 125: 522-6

19）Richeldi L, Ryerson CJ, Lee JS, et al. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax. 2012; 67: 407-11

20）Zappala CJ, Latsi PI, Nicholson AG, et al. Marginal decline in FVC is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J. 2010; 35: 830–6

21）du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011; 184（4）: 459-66

22）Taniguchi H, Kondoh Y, Ebina M, et al. The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial. Respir Res. 2011; 12: 93

23）Nishiyama O, Taniguchi H, Kondoh Y, et al. Health-related quality of life in patients with idiopathic pulmonary fibrosis. What is the main contributing factor? Respir Med. 2005; 99（4）: 408-14

24）Nishiyama O, Taniguchi H, Kondoh Y, et al. Health-related quality of life does not predict mortality in idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. In press

25）Shah NR, Noble P, Jackson RM, et al. A critical assessment of treatment options for idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2005; 22（3）: 167-74

26）谷口博之，片岡健介，近藤康博，他．特発性肺線維症の重症度分類改訂案作成に向けた症例集積．難治世疾患克服研究事業　びまん性肺疾患に関する調査研究．平成22年度研究報告書．p.67-73

27）King TE Jr, Tooze JA, Schwarz MI, et al. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med. 2001; 164（7）: 1171-81

28）Wells AU, Desai SR, Rubens MB, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med. 2003; 167（7）: 962-9

29）Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012; 156（10）: 684-91

30）Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King TE Jr, et al. Prednisone, azathioprine, and N-acetylcys­teine for pulmonary fibrosis. N Engl J Med. 2012: 366; 1968-77

31）Noth I, Anstrom KJ, Calvert SB, et al. A Placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012; 186: 88-95

32）Raghu G, Collard HR, Anstrom KJ, et al. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med. 2012; 185（10）: 1044-8

33）du Bois RM, Nathan SD, Richeldi L, el at. Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase Ⅲ trials. Am J Respir Crit Care Med. 2012; 186(8): 712-5

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp